[Form 8-K General Information](index=1&type=section&id=Form%208-K%20General%20Information) This section provides administrative and identifying information for the 8-K filing, including corporate details and stock exchange listing [Registrant and Filing Details](index=1&type=section&id=Registrant%20and%20Filing%20Details) This section provides the administrative and identifying information for STAAR Surgical Company's 8-K filing, including its corporate details, stock exchange listing, and confirmation of its non-emerging growth company status - The registrant is **STAAR Surgical Company**, incorporated in Delaware[1](index=1&type=chunk) Securities Registered | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :---------------------------------------- | | Common | STAA | NASDAQ | - The registrant is not an emerging growth company[3](index=3&type=chunk) [Reported Events and Exhibits](index=2&type=section&id=Reported%20Events%20and%20Exhibits) This section details the significant events reported in the 8-K, including financial results and accompanying exhibits [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) STAAR Surgical Company announced its preliminary net sales results for the quarter ended September 26, 2025, through a press release, which is incorporated by reference as an exhibit to this report - **STAAR Surgical Company** published a press release on October 20, 2025, reporting preliminary net sales results[4](index=4&type=chunk) - The reported results are for the quarter ended **September 26, 2025**[4](index=4&type=chunk) - The press release is filed as **Exhibit 99.1** to this report[4](index=4&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section lists the specific documents filed as exhibits to the 8-K report, including the press release detailing the preliminary financial results and the interactive data file Filed Exhibits | Exhibit Number | Exhibit Description | | :------------- | :---------------------------------------------------------- | | 99.1 | Press release of the Company dated October 20, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | [Report Signatures](index=3&type=section&id=Report%20Signatures) This section provides formal authentication of the 8-K report through authorized signatory details [Authorized Signatory Information](index=3&type=section&id=Authorized%20Signatory%20Information) The report is formally signed by an authorized representative of STAAR Surgical Company, confirming its submission in accordance with regulatory requirements - The report was signed on **October 20, 2025**[8](index=8&type=chunk) - **Stephen C. Farrell**, Chief Executive Officer, signed the report on behalf of STAAR Surgical Company[8](index=8&type=chunk)

Financial Performance - HEPLISAV-B® quarterly net product revenue reached $90 million, a 13% increase year-over-year from $79.3 million[12] - Total revenues for the third quarter of 2025 were $94.9 million, an 18% increase compared to $80.6 million for the same quarter in 2024[18] - Dynavax expects HEPLISAV-B net product revenue for the full year 2025 to be in the range of $315 to $325 million[18] - The company reported GAAP net income of $26.9 million, or $0.23 per share basic, compared to $17.6 million, or $0.13 per share basic in the third quarter of 2024[18] - Adjusted EBITDA for the third quarter of 2025 was $35.5 million, compared to $25 million for the same period in 2024[18] - Total revenues for the three months ended September 30, 2025, were $94.876 million, an increase of 17.5% compared to $80.630 million for the same period in 2024[41] - Product revenue for the three months ended September 30, 2025, was $89.954 million, up from $79.345 million in the prior year, reflecting a growth of 13.5%[41] - Adjusted EBITDA for the three months ended September 30, 2025, was $35.532 million, compared to $24.994 million for the same period in 2024, representing a year-over-year increase of 42.2%[44] - Net income for the three months ended September 30, 2025, was $26.927 million, compared to $17.594 million in the same period of 2024, marking a growth of 53.0%[41] Expenses and Liabilities - Research and development expenses for the third quarter of 2025 were $19.1 million, compared to $14.4 million in the same quarter of 2024[18] - Total current assets as of September 30, 2025, were $814.331 million, a decrease from $848.941 million as of December 31, 2024[43] - Total liabilities as of September 30, 2025, were $412.368 million, compared to $389.457 million as of December 31, 2024, indicating an increase of 5.9%[43] - Research and development expenses for the three months ended September 30, 2025, were $19.116 million, compared to $14.403 million in the same period of 2024, reflecting a 32.5% increase[41] - The company reported a loss on debt extinguishment of $82.095 million for the nine months ended September 30, 2025[44] Market Position and Strategic Initiatives - HEPLISAV-B's total estimated market share in the U.S. increased to approximately 46%, up from 44% in the third quarter of 2024[12] - Dynavax entered into an exclusive license agreement with Vaxart for its oral COVID-19 vaccine candidate, involving an upfront license fee of $25 million and potential additional payments totaling $50 million[6] - The company authorized a new $100 million share repurchase program, reflecting confidence in its future and commitment to capital allocation[7] - The company anticipates continued growth and strategic investments, including collaborations and market expansion opportunities beyond 2030[37] Cash and Securities - Cash, cash equivalents, and marketable securities totaled $647.8 million as of September 30, 2025, down from $713.8 million as of December 31, 2024[18] - Cash, cash equivalents, and marketable securities as of September 30, 2025, were $647.815 million, down from $713.834 million at the end of 2024, a decrease of 9.2%[43]

shareholder letter Q3 2025 our mission is to develop the best education in the world and make it universally available. DUOLINGO Q3 / FY 2025 2 Q3 Highlights | User Metrics | Q3 2024 | Q3 2025 | | --- | --- | --- | | Daily Active Users | 37.2M | 50.5M | | | | 36% YoY | | Monthly Active Users | 113.1M | 135.3M | | | | 20% YoY | | Paid Subscribers | 8.6M | 11.5M | | at period end | | 34% YoY | | Paid Subscriber Penetration | 8.5% | 9.0% | | as % of LTM MAUs | | | | Financial Metrics | Q3 2024 | Q3 2025 | | -- ...

Exhibit 99.1 Xencor Reports Third Quarter 2025 Financial Results PASADENA, Calif.--Nov. 5, 2025-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2025 and provided recent business and clinical program updates. "Xencor's two novel, first-in-class, CD3 T-cell engaging bispecific antibodies, XmAb819 and XmAb541, have demonstrated ...

Financial Performance - Total revenues for Q1 FY2026 reached $1.288 billion, reflecting a year-over-year increase of 1.5%[7] - Net income for the quarter was $147 million, representing a significant increase of 73.8% year-over-year, with a GAAP EPS of $0.58[7] - Adjusted EBITDA was reported at $467 million, yielding a robust margin of 36.3%[7] - Annual recurring revenues (ARR) totaled $1.071 billion, an increase of 1.8% year-over-year[8] - Gross profit for the quarter was $937,516, an increase from $910,358 in the same quarter of 2024[22] - Non-GAAP-based net income attributable to OpenText was $266,275, translating to a Non-GAAP-based earnings per share of $1.05, compared to $0.58 GAAP-based earnings per share[46] - GAAP-based net income attributable to OpenText for the three months ended September 30, 2025, was $146,616, with a net income margin of 11.4%[47] - Adjusted EBITDA for the same period was $467,411, representing an adjusted EBITDA margin of 36.3%[47] Cash Flow and Liquidity - Operating cash flows were $148 million, a remarkable increase of 289.9% year-over-year, while free cash flows reached $101 million, up 186.4%[7] - Cash flows from operating activities provided $147,763, a significant recovery from a cash outflow of $(77,806) in the prior year[29] - Total cash, cash equivalents, and restricted cash at the end of the period was $1,088,711, up from $1,002,410 a year earlier, indicating a 8.6% increase[31] - Cash used in investing activities was $(45,032), up from $(36,440) in the previous year, reflecting increased capital expenditures[29] - The company experienced a decrease in cash, cash equivalents, and restricted cash of $(69,395) during the period, a significant improvement from a decrease of $(280,383) in the same quarter last year[29] Shareholder Returns - The Board declared a cash dividend of $0.275 per common share, with a record date of December 5, 2025[10] - The company declared dividends of $0.275 per common share during the quarter, totaling $69,365[26] - The company repurchased $107,629 worth of common shares during the quarter, compared to $87,403 in the same period last year, indicating a 23.2% increase in share repurchases[29] Strategic Initiatives - The company announced a strategic divestiture of its on-premise solution (eDOCS) for $163 million as part of its portfolio-shaping strategy[11] - OpenText plans to showcase its innovation roadmap at the upcoming OpenText World User Conference, emphasizing its focus on Information Management for AI[2] Expense Management - Research and development expenses were $169,128, down from $190,693 in the prior year, indicating a focus on cost management[22] - Operating expenses for research and development totaled $169,128, while sales and marketing expenses were $257,055, reflecting ongoing investment in growth[42] Revenue Composition - Quarterly enterprise cloud bookings were $160 million, reflecting a growth of 20.2% year-over-year[7] - Revenue composition for the three months ended September 30, 2024, included 58% from USD, 24% from EURO, and 10% from other currencies[65]

JOBYAVIATION.CO iovember 5, 2025 JOBY AVIATION Shareholder Letter Q3 2025 Q3 2025 Highlights TIA aircraft begins power-on testing, marking final stage of certification process White House calls for early air taxi operations across U.S. First point-to-point flights completed Propeller manufacturing begins in Ohio Autonomous hybrid aircraft for defense applications begins ground testing Adoption of NVIDIA IGX Thor platform to supercharge autonomy capabilities Blade flies ~40,000 customers in Q3 $978 million i ...

Revenue Performance - Revenue for Q3 2025 was $737.2 million, an increase of $117.1 million, or 18.9%, from $620.1 million in Q3 2024[108] - Revenue for the nine months ended September 30, 2025, was $2,039.3 million, an increase of $453.9 million, or 28.6%, from $1,585.4 million in the same period of 2024[110] - Revenue from the storage and computing market increased by $42.6 million, or 29.6%, in Q3 2025 compared to Q3 2024, primarily due to higher sales of power solutions for storage applications[109] - Revenue from the automotive market increased by $40.2 million, or 36.1%, in Q3 2025 compared to Q3 2024, driven by higher sales supporting advanced driver assistance systems[109] - Revenue from the enterprise data market decreased by $53.0 million, or 10.2%, for the nine months ended September 30, 2025, compared to the same period in 2024[111] Profitability Metrics - Gross profit margin for Q3 2025 was 55.1%, compared to 55.4% in Q3 2024[107] - Operating income for Q3 2025 was $195.2 million, representing 26.5% of revenue, consistent with Q3 2024[107] - Net income for Q3 2025 was $178.3 million, or 24.2% of revenue, compared to $144.4 million, or 23.3% of revenue in Q3 2024[107] - Gross margin decreased to 55.1% in Q3 2025 from 55.4% in Q3 2024, primarily due to product mix[115] Expenses - Cost of revenue for Q3 2025 was $330.9 million, representing 44.9% of revenue, compared to $276.7 million or 44.6% in Q3 2024, driven by higher shipment volume[114] - R&D expenses for Q3 2025 were $98.2 million, or 13.3% of revenue, up from $85.1 million or 13.7% in Q3 2024, with increases in cash compensation and benefits[118] - SG&A expenses for Q3 2025 were $112.9 million, or 15.3% of revenue, compared to $94.4 million or 15.2% in Q3 2024, driven by higher cash compensation and stock-based compensation[122] Cash Flow and Financial Position - Net cash provided by operating activities for the nine months ended September 30, 2025, was $733.3 million, an increase of $112.6 million from the same period in 2024[131] - Total cash, cash equivalents, and short-term investments as of September 30, 2025, were $1,269.5 million, up from $862.9 million as of December 31, 2024[130] Tax and Repatriation - The income tax expense for Q3 2025 was $27.3 million, or 13.3% of pre-tax income, lower than the federal statutory rate of 21% due to tax law changes and foreign tax credits[127] - The company repatriated $275 million of cash from foreign subsidiaries to the U.S. with minimal tax impact during the nine months ended September 30, 2025[130] Future Commitments and Stock Repurchase - As of September 30, 2025, total estimated future unconditional purchase commitments were $499.3 million, with $443.2 million due within a year[138] - The Board of Directors approved a stock repurchase program of up to $500 million, with $495.3 million remaining available for future repurchases as of September 30, 2025[140] Strategic Outlook - The company plans to continue diversifying revenue across regions and product categories to mitigate risks associated with the cyclical nature of the semiconductor industry[102] - The company remains cautious regarding macroeconomic conditions, including rising inflation and global tariffs, which could impact future operations[103]

For the quarterly period ended September 30, 2025 OR Table of Contents ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-36365 SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of inc ...

Financial Performance - Net sales for the three months ended September 28, 2025, were $135,674, a decrease of 7.9% compared to $147,372 for the same period in 2024[95] - Gross profit for the current period was $3,387, representing a gross margin of 2.5%, down from 6.4% in the prior period, indicating a decline of 64.2%[95] - The operating loss increased to $9,630, compared to a loss of $3,216 in the prior period, reflecting a 199.4% increase in losses[95] - Net loss for the current period was $11,357, an increase of 48.8% from a net loss of $7,632 in the prior period[95] - Adjusted EBITDA for the three months ended September 28, 2025, was $(2,544), compared to $3,299 in the prior period, indicating a significant decline in operational performance[96] - Consolidated net sales decreased by $11,698, or 7.9%, with sales volumes down 5.2% compared to the prior period, primarily due to lower sales volumes and pricing in the Asia and Brazil segments[102] - Gross profit fell to $3,387 from $9,458 in the prior period, driven by lower sales volumes, conversion margins, and production volatility due to tariff uncertainty[104] - Adjusted EBITDA and Adjusted EPS decreased primarily due to lower gross profit[115] Restructuring and Strategic Initiatives - The company expects to incur restructuring charges between $500,000 and $1,000,000 in the second quarter of fiscal 2026, primarily related to severance costs[88] - UNIFI's strategic initiatives include expanding its presence in non-apparel markets and advancing the development of innovative and sustainable solutions[83] - UNIFI's profit improvement plan includes reducing variable manufacturing costs and eliminating a meaningful percentage of salaried positions in the U.S.[88] - Restructuring costs of $1,068 were incurred due to the closure of the Madison, North Carolina facility, including $1,021 for equipment relocation and $47 for employee separation[107] Segment Performance - Net sales in the Americas Segment were $85,196, a decrease of 1.3% from $86,283, primarily due to a lower-priced sales mix[117] - Brazil Segment net sales dropped 16.2% to $28,761, impacted by lower selling prices and sales volumes, partially offset by favorable foreign currency translation effects[119] - Asia Segment net sales decreased by 18.9% to $21,717, primarily due to lower sales volumes and competitive pricing pressures[121] Debt and Liquidity - As of September 28, 2025, UNIFI had $120,345 in debt obligations, all guaranteed by domestic operating subsidiaries[126] - The company reported total debt obligations of $120,345 million, with net debt increasing to $99,790 million from $85,344 million as of June 29, 2025[134] - UNIFI's available liquidity is $40,874 million, which includes $20,336 million from domestic operations and $20,538 million from foreign operations[127] - Cash used by operations was $8,920 for the current period, with availability under the ABL Revolver and 2024 Facility at $36,233 and $586, respectively[125] - As of September 28, 2025, total cash and cash equivalents amounted to $20,555 million, with domestic operations holding $17 million and foreign operations holding $20,538 million[127] - The company maintains a compliance status with all financial covenants in the 2022 Credit Agreement and 2024 Facility, with availability under the 2024 Facility at $586 million[133] Working Capital and Capital Expenditures - Working capital increased to $168,317 million, up from $164,684 million as of June 29, 2025, with adjusted working capital rising to $159,273 million[135] - Capital expenditures for the current period were $2,029 million, aimed at enhancing future profitability through investments in machinery and equipment[141] - The increase in adjusted working capital was primarily due to reductions in accounts payable and other current liabilities, alongside increases in inventories and receivables[136] Foreign Operations - UNIFI's foreign operations hold approximately 30.8% of total consolidated assets outside the U.S., with total cash and cash equivalents held outside the U.S. amounting to $17,985 million[150] - The weighted average exchange rate for the Brazilian Real to USD was 5.45 for the current period, compared to 5.55 in the prior period[82]

Revenue Performance - Revenue for the fiscal first quarter of 2026 was $182.5 million, an increase of 3.4% from the prior quarter and flat compared to the same quarter last year[10]. - The company expects revenue for the fiscal second quarter to be approximately $160 million, plus or minus $10 million[11]. Gross Margin - GAAP gross margin was 23.5%, up from 23.4% in the prior quarter but down from 24.5% in the same quarter last year[10]. - GAAP gross margin for the next quarter is anticipated to be 22.3%, plus or minus 1%[11]. - Estimated non-GAAP gross margin for fiscal Q2 ending December 31, 2025, is projected to be 23.0%, compared to a GAAP gross margin of 22.3%[25]. Operating Income and Expenses - Non-GAAP operating income was $2.5 million, compared to $2.3 million in the prior quarter and $7.8 million in the same quarter last year[10]. - Non-GAAP operating expenses are expected to be $40.5 million for fiscal Q2 ending December 31, 2025, down from GAAP operating expenses of $47.1 million[25]. - The company reported a non-GAAP operating income of $2,548 thousand for the three months ended September 30, 2025, compared to $7,809 thousand in the same period of 2024, reflecting a decrease of 67%[22]. Cash Flow and Assets - Consolidated cash flows provided by operating activities was $10.2 million, compared to cash flows used in operating activities of $2.8 million in the prior quarter[10]. - Total current assets increased to $531,284 thousand as of September 30, 2025, up from $396,162 thousand as of June 30, 2025, representing a 34% increase[19]. - Cash, cash equivalents, and restricted cash at the end of the period increased to $223,930 thousand, up from $176,222 thousand in the same period of 2024, marking a 27% increase[21]. Liabilities - Total liabilities decreased to $203,445 thousand as of September 30, 2025, down from $211,971 thousand as of June 30, 2025, a reduction of approximately 4%[19]. Net Income and Loss - GAAP net loss for the three months ended September 30, 2025, was $2,122 thousand, a significant improvement compared to a net loss of $77,059 thousand in the previous quarter[22]. - Non-GAAP net income for the three months ended September 30, 2025, was $4,176 thousand, compared to $6,421 thousand in the same period of 2024, indicating a decline of 35%[22]. Strategic Focus - The company is focusing on extending its leadership into higher-growth areas including graphics, AI, and data-center power[7]. Interest Income - Interest income is expected to exceed interest expense by $1.0 million in the upcoming quarter[11]. Power IC Revenue - Power IC revenue increased 37.3% year-over-year, now representing nearly 40% of total product revenue[7].